We added FDA's July 2026 pharmacy-compounding review and changed the display status from identity-only to a pending safety review without implying a final FDA determination.
PeptideScanner change date
July 29, 2026
Evidence lane
Profile
Status
Before
FDA identity record only; approval status not established
After
FDA compounding safety review; final determination pending
Status classification
Before
identity-only
After
safety-review
Topic
Before
Identity records
After
Safety records
Profile summary
Before
A research-peptide name that FDA's substance registry maps to a thymosin beta-4 fragment.
After
A thymosin beta-4 fragment represented in FDA identity and pharmacy-compounding review records.
Evidence note
Before
FDA's substance registry identifies TB-500 as an N-terminal acetylated 17-23 fragment of thymosin beta-4 and explicitly states that a UNII record does not imply regulatory review or approval.
After
FDA's identity record maps TB-500 to a thymosin beta-4 fragment, while FDA's July 2026 briefing addresses its pharmacy-compounding review. Committee recommendations are nonbinding, and FDA's final determination remains pending.
Showing the latest 7 additions by PeptideScanner publication date; the complete connected record set remains available in Latest Research. Most recent addition: August 21, 2026.
The Federal Register published notice 2026-07361, attributed to FDA and its parent HHS department, on 2026-04-16. Its official title is “Pharmacy Compounding Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments-Bulk Drug Substances Nominated for Inclusion on the Section 503A Bulk Drug Substances List,” and PeptideScanner's exact reviewed identity mapping connects the document to BPC-157, Emideltide, Epitalon, KPV, MOTS-c, Semax and TB-500.
PeptideScanner retained ClinicalTrials.gov record NCT07487363 at 2026-07-30T16:22:22.342Z. Its registry update date was 2026-03-23, and PeptideScanner's reviewed identity mapping was tb-500.
PeptideScanner retained PubMed bibliographic metadata for PMID 22962027 at 2026-07-30T16:30:49.822Z. PubMed recorded a metadata revision date of 2026-01-28 and an Entrez history date of 2012-09-11. PeptideScanner associated this retained record with the identity slug tb-500. These dates describe PubMed metadata history, not the article's original publication date.
PeptideScanner retained PubMed bibliographic metadata for PMID 23084823 at 2026-07-30T16:30:49.836Z. PubMed recorded a metadata revision date of 2026-01-28 and an Entrez history date of 2012-10-23. PeptideScanner associated this retained record with the identity slug tb-500. These dates describe PubMed metadata history, not the article's original publication date.
PeptideScanner retained PubMed bibliographic metadata for PMID 28887173 at 2026-07-30T21:13:36.164Z. PubMed recorded a metadata revision date of 2018-02-08 and an Entrez history date of 2017-09-10. PeptideScanner associated this retained record with the identity slug tb-500. These dates describe PubMed metadata history, not the article's original publication date.
PeptideScanner retained PubMed bibliographic metadata for PMID 38382158 at 2026-07-30T18:48:13.580Z. PubMed recorded a metadata revision date of 2024-03-11 and an Entrez history date of 2024-02-21. PeptideScanner associated this retained record with the identity slug tb-500. These dates describe PubMed metadata history, not the article's original publication date.
FDA convened its Pharmacy Compounding Advisory Committee on July 23-24, 2026, to discuss free-base and acetate bulk drug substances across seven peptide-related groups.